{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "R",
          "position": "240"
        },
        "variant_string_id": "PARK2 T240R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) is characterized by selective dopaminergic neural cell death and the absence of Lewy bodies. Mutations in PARK2 cause AR-JP, and parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with UbcH7. Loss of this activity leads to accumulation of unidentified proteins causing neural cell death.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to defective protein degradation due to loss of parkin’s ubiquitin-protein ligase activity, leading to accumulation of proteins and selective neural cell death."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses co-immunoprecipitation assays to test parkin interaction with UbcH7 and in vitro ubiquitination assays to demonstrate E3 ligase activity of parkin, focusing on its role in protein degradation.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (co-immunoprecipitation and in vitro ubiquitination) directly models the disease mechanism by assessing parkin’s E3 ligase activity and interaction with UbcH7, which are central to the protein degradation defect in AR-JP.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper describes the use of wild-type parkin as a control in co-immunoprecipitation and ubiquitination assays (Figs. 1, 2, 5). However, there is no explicit mention of abnormal/positive/null controls like known loss-of-function mutants in these assays for T240R. Additionally, there is no explicit statement on the use of multiple replicates for experiments.",
          "judgment": "No",
          "reasoning": "While wild-type parkin serves as a normal control, the paper does not explicitly describe abnormal/positive/null controls for the T240R variant assays. Furthermore, there is no mention of replicates (e.g., 'performed in triplicate' or 'n=3 independent experiments'), failing to meet both criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The paper does not state that the specific co-immunoprecipitation or in vitro ubiquitination assays for parkin are broadly accepted historically, previously validated in other studies, or provided as commercial kits with defined performance metrics.",
          "judgment": "No",
          "reasoning": "There is no evidence in the paper that the specific assays used for T240R are historically accepted, previously validated, or part of a commercial kit with defined metrics. Thus, the assay instance cannot be considered validated without controls and replicates.",
          "next_step_or_outcome": "Do not use PS3/BS3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "N/A"
      },
      "overall_conclusion": "The functional evidence for PARK2 T240R cannot be used for PS3 classification due to insufficient basic controls (lack of abnormal/positive/null controls) and lack of explicit replicates in the assays. Additionally, the specific assay instance is not described as broadly accepted or validated, leading to a determination of 'Do not use PS3/BS3'."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) is characterized by selective dopaminergic neural cell death and the absence of Lewy bodies. Mutations in PARK2 cause AR-JP, and parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with UbcH7. Loss of this activity leads to accumulation of unidentified proteins causing neural cell death.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to defective protein degradation due to loss of parkin’s ubiquitin-protein ligase activity, leading to accumulation of proteins and selective neural cell death."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses co-immunoprecipitation assays to test parkin interaction with UbcH7 and in vitro ubiquitination assays to demonstrate E3 ligase activity of parkin, focusing on its role in protein degradation.",
          "judgment": "Yes",
          "reasoning": "The general class of assays (co-immunoprecipitation and in vitro ubiquitination) directly models the disease mechanism by assessing parkin’s E3 ligase activity and interaction with UbcH7, which are central to the protein degradation defect in AR-JP.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper describes the use of wild-type parkin as a control in co-immunoprecipitation and ubiquitination assays (Figs. 1, 2, 5). However, there is no explicit mention of abnormal/positive/null controls like known loss-of-function mutants in these assays for R42P. Additionally, there is no explicit statement on the use of multiple replicates for experiments.",
          "judgment": "No",
          "reasoning": "While wild-type parkin serves as a normal control, the paper does not explicitly describe abnormal/positive/null controls for the R42P variant assays. Furthermore, there is no mention of replicates (e.g., 'performed in triplicate' or 'n=3 independent experiments'), failing to meet both criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The paper does not state that the specific co-immunoprecipitation or in vitro ubiquitination assays for parkin are broadly accepted historically, previously validated in other studies, or provided as commercial kits with defined performance metrics.",
          "judgment": "No",
          "reasoning": "There is no evidence in the paper that the specific assays used for R42P are historically accepted, previously validated, or part of a commercial kit with defined metrics. Thus, the assay instance cannot be considered validated without controls and replicates.",
          "next_step_or_outcome": "Do not use PS3/BS3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "N/A"
      },
      "overall_conclusion": "The functional evidence for PARK2 R42P cannot be used for PS3 classification due to insufficient basic controls (lack of abnormal/positive/null controls) and lack of explicit replicates in the assays. Additionally, the specific assay instance is not described as broadly accepted or validated, leading to a determination of 'Do not use PS3/BS3'."
    }
  ]
}